Drawing for MASSAFFINITY

USPTO serial 79387519

MASSAFFINITY

Reviewed by CopyMark Law Group

Reg. 7756854Status 700Registered
Filing date
Status date
Registration date
Apr 15, 2025
Examiner
BLOHM, LINDA
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MASSAFFINITY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew A. Homyk

Matthew A. Homyk Blank Rome LLPOne Logan Square600 Bourke StreetPhiladelphia, PA 19103

Goods and services

ClassDescriptionStatusFirst use
001Laboratory chemicals for scientific use, namely, chemical preparations for scientific purposes, other than for medical or veterinary use; chemical preparations for analyses in laboratories for scientific purposes, other than for medical or veterinary purposes; proteins for use in science; chemical preparations for use in the pharmaceutical industry; chemicals for use in the pharmaceutical industry; chemicals for use in industryACTIVE—
005Chemical preparations for medical analysis purposes, namely, for mass spectrometry-based screening of molecular targets associated with diseases; chemicals for use in medical analysis purposes, namely, for mass spectrometry-based screening of molecular targets associated with diseases; chemical preparations for pharmaceutical purposes, namely, for identifying therapeutics for molecular targets associated diseases using mass-spectrometry-based screening; medical diagnostics preparations for the analysis of bodily fluidsACTIVE—
009Apparatus for scientific use, namely, mass spectrometry apparatus for scientific purposes, ionization apparatus for scientific use, ultra-high vacuum chambers for scientific purposes, scientific apparatus for measuring relative DNA, RNA, ligands and protein and parts and fittings therefor, fluid handling device used for disposable bioprocessing applications and parts and fittings therefor, mass spectrometers and parts and fittings therefor; instruments for scientific research in laboratories; apparatus for scientific research in laboratories, namely, scientific laboratory research instruments for detecting pathogens and DNA analysis; laboratory apparatus for scientific research, namely, laboratory apparatus for the exchange of substances, laboratory apparatus and instruments for extracting DNA, not for medical purposesACTIVE—
010Apparatus, namely, mass spectrometers, proteomics platforms and ionization sources, microplates, microplate handling equipment, automated liquid handling platform, incubators, electronic balances and microscopes each for carrying-out assays for medical purposes; medical instruments for use in mass spectrometry-based screening; medical instruments, namely, centrifuges and microcentrifuge tubes, pipettes, pH meters, spectrophotometers, magnetic stirrers, and mini shakersACTIVE—
042Analysis of tissues for medical research; design and development of computer software; design of computer hardware; pharmaceutical research services; research in the field of artificial intelligence technology; research relating to molecular sciences; medical research; scientific research consulting; scientific research, including scientific research for medical purposes in the fields of early drug discovery for pharmaceuticals and biotechnology for unmet medical needs across all disease areasACTIVE—
044Medical analysis services relating to the treatment of persons; pharmaceutical advisory servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 15, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 29, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 29, 2025FIMPFINAL DISPOSITION PROCESSED—
Jul 15, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 4, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jun 17, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jun 17, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 15, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 15, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 25, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 25, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 19, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 30, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 21, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 21, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 21, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 25, 2024RFNTREFUSAL PROCESSED BY IB—
Aug 6, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 5, 2024RFRRREFUSAL PROCESSED BY MPU—
Jul 16, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 15, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 15, 2024DOCKASSIGNED TO EXAMINER—
Jan 23, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 19, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 18, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance